Frost & Sullivan has recognized Olink Proteomics with its 2018 Global Enabling Technology Leadership Award for the development of our multiplex cardiovascular disease (CVD) panels. Each year, Frost & Sullivan presents this award to a company that develops a pioneering technology that not only enhances current products but also enables new products and application development.
The Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
Olink is delighted to get this award, which reflects the impact of the Olink® CVD II and Olink® CVD III panels on clinical research within the CVD field.
According to Unmesh Lal (Transformational Health Program Manager at Frost & Sullivan), “Olink Proteomics’ delivers an unparalleled high-scale multiplex, high-throughput opportunity for protein research with meager biobank consumption. By providing quick, accurate, and concurrent investigation on a range of 92 proteins in each CVD panel, with high specificity through its novel technology platform, Olink Proteomics unleashes new frontiers of research in precision medicine.”
The award will be presented to Olink Proteomics CEO Jon Heimer at a ceremony to be held at the Grand Hyatt, San Antonio, TX on December 3, 2018.